{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:39:27Z","timestamp":1790800767050,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunoglobulin A (IgA) nephropathy is a common autoimmune kidney disease. Accumulating studies showed that IgA nephropathy may be partially correlated with mucosal immune system dysfunction. Systemic corticosteroid treatment exerts an essential protective effect against renal deterioration in IgA nephropathy. However, long-term use of corticosteroids may cause systemic side effects. The novel targeted-release formulation (TRF) of budesonide has been shown to deliver the drug to the distal ileum with the aim of minimizing adverse events for patients with IgA nephropathy. In this review, we have summarized all the current evidence of the effects of TRF-budesonide protecting against IgA nephropathy. Three randomized controlled trials (RCTs), one cohort, two case reports, and an ongoing Phase 3 trial (Part B, NCT03643965), were under comprehensive review. These included studies demonstrated that TRF-budesonide could remarkably reduce proteinuria, hematuria, and creatinine, as well as preserve renal function. The local immunosuppressive effects exhibited by TRF-budesonide may represent a novel and promising approach to treating IgA nephropathy. However, the current evidence was only derived from limited trials. Therefore, more well-designed RCTs are still warranted to validate the curable profile of TRF-budesonide in treating IgA nephropathy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.926517","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T10:01:56Z","timestamp":1672826516000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jian","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","article-title":"[Intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the international kidney biopsy survey","volume":"33","author":"O'Shaughnessy","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.07.011","article-title":"IgA nephropathy enigma","volume":"172","author":"Mestecky","year":"2016","journal-title":"Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs437","article-title":"Incidence of primary glomerulonephritis in a large north-Eastern Italian area: a 13-year renal biopsy study","volume":"28","author":"Zaza","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PloS Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis PRIMERS."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.07.012","article-title":"IgA nephropathy genetic risk score to estimate the prevalence of IgA nephropathy in UK biobank","volume":"5","author":"Sukcharoen","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc NEPHROL."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2015.02.007","article-title":"Immunoglobulin a nephropathy: current progress and future directions","volume":"166","author":"Zhang","year":"2015","journal-title":"Transl Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194501","article-title":"Athogenesis of IgA nephropathy: Current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0726-5","article-title":"Improved renal survival in Japanese children with IgA nephropathy","volume":"23","author":"Yata","year":"2008","journal-title":"Pediatr NEPHROL."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: An interesting autoimmune kidney disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am J Med Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.39","article-title":"Structure and function relationships in IgA","volume":"4","author":"Woof","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3628-1","article-title":"Inflammation in IgA nephropathy","volume":"32","author":"Rauen","year":"2017","journal-title":"Pediatr NEPHROL."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107282","article-title":"Immune characteristics of renal allograft donors with mesangial IgA deposition","volume":"91","author":"Wang","year":"2021","journal-title":"Int IMMUNOPHARMACOL."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part a of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin a nephropathy","volume":"19","author":"Barratt","year":"2022","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2018.05.020","article-title":"The gut-renal connection in IgA nephropathy","volume":"38","author":"Coppo","year":"2018","journal-title":"Semin NEPHROL."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021081086","article-title":"Galactose-deficient IgA1 b cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors","volume":"33","author":"Zachova","year":"2022","journal-title":"J Am Soc NEPHROL."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.732977","article-title":"Anti-FcalphaRI monoclonal antibodies resolve IgA autoantibody-mediated disease","volume":"13","author":"Bos","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/iji.12561","article-title":"Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link","volume":"49","author":"Selvaskandan","year":"2022","journal-title":"Int J IMMUNOGENET."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190967","article-title":"Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy","volume":"13","author":"Placzek","year":"2018","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13987","article-title":"Immunoglobulin a nephropathy in paediatrics: An up-to-date","volume":"27","author":"Paranhos","year":"2022","journal-title":"Nephrol (Carlton)."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.3.1387","article-title":"Increased frequency of surface IgA-positive plasma cells in the intestinal lamina propria and decreased IgA excretion in hyper IgA (HIGA) mice, a murine model of IgA nephropathy with hyperserum IgA","volume":"165","author":"Kamata","year":"2000","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099006","article-title":"Microbiota and metabolome associated with immunoglobulin a nephropathy (IgAN)","volume":"9","author":"De Angelis","year":"2014","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02970.x","article-title":"Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis","volume":"66","author":"Cheng","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-019-02094-5","article-title":"Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis","volume":"51","author":"Qian","year":"2019","journal-title":"Int UROL NEPHROL."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.23","article-title":"Chapter 10: Immunoglobulin a nephropathy","volume":"2","year":"2012","journal-title":"Kidney Int Suppl 2011"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.026","article-title":"Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy","volume":"100","author":"Kano","year":"2021","journal-title":"Kidney Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04660513","article-title":"The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease","volume":"9","author":"Ambruzs","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu343","article-title":"The intestine-renal connection in IgA nephropathy","volume":"30","author":"Coppo","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2.1.159","article-title":"TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract","volume":"2","author":"Watts","year":"2005","journal-title":"Expert Opin Drug Deliv."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.34","article-title":"Budesonide in the treatment of inflammatory bowel disease","volume":"7","author":"Silverman","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14151","article-title":"Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician","volume":"33","author":"Miehlke","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"LANCET."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021000","article-title":"Budesonide versus systemic corticosteroids in IgA nephropathy: A retrospective, propensity-matched comparison","volume":"99","author":"Ismail","year":"2020","journal-title":"Med (Baltimore)."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/jpc.14259","article-title":"Childhood IgA nephropathy successfully treated with targeted-release budesonide: A case report","volume":"54","author":"Venettacci","year":"2018","journal-title":"J Paediatr Child Health"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.284029","article-title":"Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide","volume":"31","author":"Lingaraj","year":"2020","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003965.pub3","article-title":"Mmunosuppressive agents for treating IgA nephropathy","volume":"3","author":"Natale","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.21037\/atm-22-1028","article-title":"Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment","volume":"10","author":"Feng","year":"2022","journal-title":"Ann Transl Med"},{"key":"B50","first-page":"79","article-title":"Recurrent glomerulonephritis in living kidney transplantation","volume":"26","author":"Spasovski","year":"2005","journal-title":"Prilozi."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.926517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T10:01:59Z","timestamp":1672826519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.926517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2022.926517"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.926517","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"926517"}}